Source: International Congress 2018 – Clinical news in idiopathic interstitial pneumonias
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Ntolios (Alexandroupolis, Greece), E. Manoloudi (Alexandroupolis, Greece), A. Tzouvelekis (Athens, Greece), E. Bouros (Athens, Greece), P. Steiropoulos (Alexandroupolis, Greece), S. Anevlavis (Alexandroupolis, Greece), D. Bouros (Athens, Greece), M. Froudarakis (Alexandroupolis, Greece). Longitudinal outcomes of patients enrolled in a phase Ib clinical trial of the Adipose Derived Stromal Cells-Stromal Vascular Fraction in Idiopathic Pulmonary Fibrosis. 545

Member's Comments

No comment yet.

Related content which might interest you: Predictors of Residual Pulmonary Vascular Obstruction after Pulmonary Embolism: results from a prospective cohort study Source: Virtual Congress 2020 – Pulmonary embolism Year: 2020 Clinical Features and Prognosis of Acute exacerbation of Connective Tissue Diseases Associated Pulmonary Fibrosis------ Comparision with Idiopathic Pulmonary Fibrosis Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 The impact of Initial Pulmonary Vascular Obstruction on the Risk of Recurrence of Pulmonary Embolism: a French prospective cohort. Source: Virtual Congress 2020 – From diagnosis to management of pulmonary embolism Year: 2020 Clinical and Epidemiological Features of Tumor and Non-tumor Patients Complicated with Pulmonary Embolism Source: International Congress 2017 – Prognostic factors and outcomes in pulmonary embolism Year: 2017 Multi-Omics Analysis of the PDGF Response in Pulmonary Vascular Smooth Muscle Cells from Patients with Pulmonary Arterial Hypertension: Implication of the NMDAR Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Clinical profile and early follow-up of patients receiving pirfenidone in the PIONEER observational study Source: International Congress 2014 – ILDs 6 Year: 2014 Prognostic Factors in Patients with Idiopathic Pulmonary Fibrosis; Evaluation using Quantitative CT Analysis of Fibrosis and Emphysema Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Clinical characteristics of a Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH)  Cohort Source: Virtual Congress 2020 – Addressing unresolved questions in rare diffuse parenchymal lung diseases: interdisciplinary research is the key Year: 2020 Lung cancer in patients with Idiopathic Pulmonary Fibrosis. A retrospective multicenter study Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 Effect of Pulmonary Rehabilitation on Functional Exercise Capacity and Hypoxemia in Patients with Interstitial Lung Diseases: a retrospective study Source: International Congress 2018 – Aspects of pulmonary rehabilitation and chronic care Year: 2018 Pirfenidone in Chronic Lung Allograft Dysfunction after Lung Transplantation: A single-centre experience. Source: International Congress 2017 – The ongoing struggle: insights into chronic lung allograft dysfunction (CLAD) Year: 2017 LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014 Effects of Telerehabilitation on Peripheral Muscle Function in Pediatric Cystic Fibrosis Patients During Covid-19 Pandemic Source: Virtual Congress 2021 – Physical activity, exercise training and (tele)rehabilitation in respiratory patients Year: 2021 Late Breaking Abstract - Blood Eosinophils as Predictor of Outcomes in hospitalized COPD Exacerbations: Results from a Prospective Study Source: International Congress 2019 – Eosinophils and FeNO in airway diseases Year: 2019 Diffuse Pulmonary Non-Amyloid Light-Chain Deposition Disease: Phenotypes and Outcome Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases Year: 2021 Associated Factors with the Approval of Pulmonary Rehabilitation for Inpatients with Interstitial Lung Disease: Two-center Retrospective Study Source: International Congress 2018 – What’s hot in rehabilitation in COPD and interstitial lung disease (ILD)? Year: 2018 Association between Pulmonary Infections and the Prognosis in Patients with Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Nintedanib in Idiopathic Pulmonary Fibrosis: a single-centre real-life experience Source: International Congress 2017 – IPF: from the bench to the bedside Year: 2017 Interdisciplinary Pilot Project on Emphysema Quantification and Bronchial Wall Thickness assessment in COPD patients Source: International Congress 2018 – Biomarkers of COPD Year: 2018